BPRxTM

A novel phyto-endocannabinoid drug combinatory platform.

BPRxTM-060234

Lead compound for treating Alzheimer’s Disease.

BPRxTM-060312

Biotica has created an opiate addiction initiative.

BPRxTM-060216

Lead compound for treating Eosinophilic Esophagitis.

About Biotica

Biotica is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica has set-up a state-of-the-art research and development lab to enhance the BPRxTM platform and is rapidly expanding its research capabilities. Biotica’s research includes specific programs for eosinophilic esophagitis, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRxTM platform to optimize the synergistic combination of phyto and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisers, and board directors are working to accelerate breakthrough treatments for patients with significant unmet medical needs.

BPRxTM

The endocannabinoid system (ECS) is composed of two G protein-coupled receptors (GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid ligands of such receptors, anandamide and 2-arachidonoyl-glycerol(2-AG). The ECS is a pleiotropic signalling system involved in all aspects of mammalian physiology and pathology.

BPRxTM-060234

Alzheimer’s disease (AD) represents a complex class of debilitating brain diseases that mostly affects people aged 65 and older. AD is characterized by progressive loss of neurons in the hippocampus and cortex, which results in the shrinkage of brain. Basically, the brain cells required to process, store and retrieve information are killed.

BPRxTM-060216

Eosinophilic Esophagitis (EoE) also known as “asthma of the esophagus” is a chronic immune mediated disorder of the esophagus affecting both children and adults. EoE is a major cause of chronic esophagitis, second to gastro-esophageal reflux. Patients present with abdominal pain, vomiting, and dysphagia, difficulty swallowing and food impaction.

BPRxTM-060312

Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. Biotica’s preliminary studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids.

LATEST HEALTH NEWS

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes.

Sharpen your thinking skills

Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus. Proin viverra nisi at nisl imperdiet auctor....

Medicines could save billions

Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus. Proin viverra nisi at nisl imperdiet auctor....

The problem with painkillers

Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus. Proin viverra nisi at nisl imperdiet auctor....

Therapies for neck pain

Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus. Proin viverra nisi at nisl imperdiet auctor....

P.C. Sundareswaran, Ph.D.
CEO and President
Learn More
Paul Carney, Ph.D.
Chief Medical and Clinical Officer
Learn More
Bobban Subhadra, Ph.D.
Chief Technology Officer
Learn More
John Verghese
COO
Learn More
Deirdre Fernandes
Vice President of Operations
Learn More
Christopher Anderson, M.S., Ph.D.
Clinical Director
Learn More

INVESTOR RELATIONS

Biotica welcomes strategic partners and investors to advance the discovery and development of its novel platform technologies for unmet market needs. With our state-of-the art lab facilities and world class team, we will be an ideal strategic partner for joint development collaborations and strategic investors exploring innovative approaches that fits with their development portfolio.